ChAdOx2 HAV / University of Oxford, HAV Vaccines - LARVOL DELTA

A phase 1b clinical trial to determine the safety, tolerability and immunogenicity of simian adenovirus and poxvirus vectored vaccines against Mycobacterium avium complex subspecies in patients with active Crohn's disease. (PubMed, EBioMedicine) - "Candidate vaccines ChAdOx2 HAV and MVA HAV were safe, well-tolerated and immunogenic in patients with active CD. A heterologous prime-boost schedule induces a T cell-mediated immune response. Further studies are required to determine the efficacy and optimal regime of the vaccines."

Journal • P1 data • Crohn's disease • Gastroenterology • Gastrointestinal Disorder • Immunology • Infectious Disease • Inflammatory Bowel Disease • Respiratory Diseases • Tuberculosis

Safety and Immunogenicity of Adenovirus and Poxvirus Vectored Vaccines against a Mycobacterium Avium Complex Subspecies. (PubMed, Vaccines (Basel)) - "Here we report on safety and immunogenicity of the poxvirus Modified Vaccinia Ankara (MVA) vectored vaccine expressing four Mycobacterium avium subspecies paratuberculosis antigens as a single dose or as a booster vaccine following a simian adenovirus (ChAdOx2) prime. We demonstrate that a heterologous prime-boost schedule is well tolerated and induced T-cell immune responses."

Clinical • Journal • Infectious Disease • Respiratory Diseases • Tuberculosis

A Phase Ib Study of the Safety and Immunogenicity of the Candidate Rabies Vaccine ChAdOx2 RabG (clinicaltrials.gov) - P1; N=48; Not yet recruiting; Sponsor: University of Oxford; Trial completion date: Oct 2021 ➔ Apr 2022; Initiation date: Nov 2020 ➔ Mar 2021; Trial primary completion date: Oct 2021 ➔ Apr 2022

Clinical • Head-to-Head • Trial completion date • Trial initiation date • Trial primary completion date

Safety and Immunogenicity of the Candidate Rabies Vaccine ChAdOx2 RabG (clinicaltrials.gov) - P1; N=12; Active, not recruiting; Sponsor: University of Oxford; Recruiting ➔ Active, not recruiting; N=18 ➔ 12; Trial completion date: Jun 2021 ➔ Sep 2021; Trial primary completion date: Jun 2021 ➔ Sep 2021

Clinical • Enrollment change • Enrollment closed • Trial completion date • Trial primary completion date

A Phase Ib Study of the Safety and Immunogenicity of the Candidate Rabies Vaccine ChAdOx2 RabG (clinicaltrials.gov) - P1; N=48; Not yet recruiting; Sponsor: University of Oxford; Initiation date: Apr 2020 ➔ Nov 2020

Trial initiation date

A Study to Determine the Safety and Immunogenicity of a Candidate MAP Vaccines ChAdOx2 HAV and MVA in Healthy Adult Volunteers (clinicaltrials.gov) - P1; N=28; Completed; Sponsor: University of Oxford; Recruiting ➔ Completed

Clinical • Trial completion

A Phase Ib Study of the Safety and Immunogenicity of the Candidate Rabies Vaccine ChAdOx2 RabG (clinicaltrials.gov) - P1; N=48; Not yet recruiting; Sponsor: University of Oxford

Clinical • Head-to-Head • New P1 trial

Safety and Immunogenicity of the Candidate Rabies Vaccine ChAdOx2 RabG (clinicaltrials.gov) - P1; N=18; Recruiting; Sponsor: University of Oxford; Not yet recruiting ➔ Recruiting

Clinical • Enrollment open

Safety and Immunogenicity of the Candidate Rabies Vaccine ChAdOx2 RabG (clinicaltrials.gov) - P1; N=18; Not yet recruiting; Sponsor: University of Oxford

Clinical • New P1 trial

A Study to Determine the Safety and Immunogenicity of a Candidate MAP Vaccines ChAdOx2 HAV and MVA in Healthy Adult Volunteers (clinicaltrials.gov) - P1; N=28; Recruiting; Sponsor: University of Oxford; Trial completion date: Sep 2019 ➔ Jan 2020; Trial primary completion date: Sep 2019 ➔ Jan 2020

Clinical • Trial completion date • Trial primary completion date